In recent years, the association between the efficacy of immune checkpoint inhibitors (ICIs), such as therapies targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and the presence or localization of TLSs has garnered increasing attention in cancer treatment. Here, PDCD1 is linked to cancer.